These findings support the reliability and potential clinical applicability of our radiomics prediction model for CTLA4 expression in HNSCC, indicating its usefulness in personalized prognostic assessment and treatment decision-making. This evidence concerns the gene CTLA4 and head and neck squamous cell carcinoma.